The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Increased expression of PPARγ in high fat diet-induced liver steatosis in mice
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hepatic PPARγ plays important roles in HFD-induced up-regulation of lipogenic genes and de novo lipogenesis.
“and this may also have contributed to the reduced hepatic lipogenesis, as hepatic PPARγ plays important roles in HFD-induced up-regulation of lipogenic genes and de novo lipogenesis.53–55”
From (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis (2018) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Flagged first, then by citations
Research works printed but not linked: 32
- Lemberger, 1996, Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology, Annu. Rev. Cell. Dev. Biol., 12, 335, 10.1146/annurev.cellbio.12.1.335 · DOI
- Spiegelman, 1996, Adipogenesis and obesity: rounding out the big picture, Cell, 84, 377, 10.1016/S0092-8674(00)81359-8 · DOI
- Tontonoz, 1994, mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer, Genes Dev., 8, 1224, 10.1101/gad.8.10.1224 · DOI
- Zhu, 1995, Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms, Proc. Natl. Acad. Sci. USA, 92, 7921, 10.1073/pnas.92.17.7921 · DOI
- Rosen, 2002, C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway, Genes Dev., 16, 22, 10.1101/gad.948702 · DOI
- Nolan, 1994, Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone, N. Engl. J. Med., 331, 1188, 10.1056/NEJM199411033311803 · DOI
- Ricote, 1998, The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation, Nature, 391, 79, 10.1038/34178 · DOI · Paper page
- Xin, 1999, Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo, J. Biol. Chem., 274, 9116, 10.1074/jbc.274.13.9116 · DOI
- Li, 2000, Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice, J. Clin. Invest., 106, 523, 10.1172/JCI10370 · DOI
- Sarraf, 1998, Differentiation and reversal of malignant changes in colon cancer through PPARgamma, Nat. Med., 4, 1046, 10.1038/2030 · DOI
- Brockman, 1998, Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells, Gastroenterology, 115, 1049, 10.1016/S0016-5085(98)70072-1 · DOI
- Tontonoz, 1997, Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptorγ and the retinoid X receptor, Proc. Natl. Acad. Sci. USA, 94, 237, 10.1073/pnas.94.1.237 · DOI
- Takahashi, 1999, Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells, FEBS Lett., 455, 135, 10.1016/S0014-5793(99)00871-6 · DOI
- Motomura, 2000, Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells, Cancer Res., 60, 5558
- Motomura, 2004, Growth arrest by troglitazone is mediated by p27Kip1 accumulation which is resulted from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells, Int. J. Cancer, 108, 41, 10.1002/ijc.11561 · DOI
- Memon, 2000, Endocrinology, 141, 4021, 10.1210/endo.141.11.7771 · DOI
- Rahimian, 2001, Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus, Mol. Cell. Biochem., 224, 29, 10.1023/A:1011927113563 · DOI
- Chao, 2000, Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones, J. Clin. Invest., 106, 1221, 10.1172/JCI11245 · DOI
- Burant, 1997, Troglitazone action is independent of adipose tissue, J. Clin. Invest., 100, 2900, 10.1172/JCI119839 · DOI
- Bedoucha, 2001, Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones, J. Hepatol., 35, 17, 10.1016/S0168-8278(01)00066-6 · DOI
- Matsusue, 2003, Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes, J. Clin. Invest., 111, 737, 10.1172/JCI200317223 · DOI · Paper page
- Yu, 2003, Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression, J. Biol. Chem., 278, 498, 10.1074/jbc.M210062200 · DOI
- Angulo, 2002, Nonalcoholic fatty liver disease, N. Engl. J. Med., 346, 1221, 10.1056/NEJMra011775 · DOI · Paper page
- Bedoucha, 2001, Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones, J. Hepatol., 38, 17, 10.1016/S0168-8278(01)00066-6 · DOI
- Takahashi, 2004, A novel aminosterol reverses diabetes and fatty liver disease in obese mice, J. Hepatol., 41, 391, 10.1016/j.jhep.2004.05.006 · DOI
- Gregoire, 2002, Diet-induced obesity and hepatic gene expression alterations in C57BL/6J and ICAM-1-deficient mice, Am. J. Physiol., 282, E703
- Herzig, 2003, CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma, Nature, 426, 190, 10.1038/nature02110 · DOI
- Matsui, 2004, Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet, Diabetes, 53, 2844, 10.2337/diabetes.53.11.2844 · DOI
- Nicholson, 2001, Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis, Ann. N. Y. Acad. Sci., 947, 224, 10.1111/j.1749-6632.2001.tb03944.x · DOI
- Motojima, 1998, Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner, J. Biol. Chem., 273, 16710, 10.1074/jbc.273.27.16710 · DOI
- Walczak, 2002, PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism, J. Lipid Res., 43, 177, 10.1016/S0022-2275(20)30159-0 · DOI
- Herzig, 2001, CREB regulates hepatic gluconeogenesis through the coactivator PGC-1, Nature, 413, 179, 10.1038/35093131 · DOI · Paper page
Cited by
Sorted by citations
Rivera, C. A., Adegboyega, P., van Rooijen, N., Tagalicud, A., Allman, M., & Wallace, M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.019 · Cited by 693
Systems proteomics of liver mitochondria function
Williams, E. G., Wu, Y., Jha, P., Dubuis, S., Blattmann, P., Argmann, C. A., Houten, S. M., Amariuta, T., Wolski, W., Zamboni, N., et al. (2016) · Science · doi:10.1126/science.aad0189 · Cited by 289
Impact of nutrients on circadian rhythmicity
Oosterman, J. E., Kalsbeek, A., la Fleur, S. E., & Belsham, D. D. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00322.2014 · Cited by 221
Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H., & Sasaoka, T. (2010) · Endocrinology · doi:10.1210/en.2009-0869 · Cited by 189
Targeting fatty acid metabolism to improve glucose metabolism
Stinkens, R., Goossens, G. H., Jocken, J. W. E., & Blaak, E. E. (2015) · Obesity Reviews · doi:10.1111/obr.12298 · Cited by 183
IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis
Gao, Y., Liu, Y., Yang, M., Guo, X., Zhang, M., Li, H., Li, J., & Zhao, J. (2016) · Oncotarget · doi:10.18632/oncotarget.9259 · Cited by 79
Dysregulation of systemic iron metabolism in alcoholic liver diseases
Kohgo, Y., Ohtake, T., Ikuta, K., Suzuki, Y., Torimoto, Y., & Kato, J. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05290.x · Cited by 66
Self-citationRen, L., Sun, Y., Lu, H., Ye, D., Han, L., Wang, N., Daugherty, A., Li, F., Wang, M., Su, F., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312422 · Cited by 59
Samson, S. L., Gonzalez, E. V., Yechoor, V., Bajaj, M., Oka, K., & Chan, L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.198 · Cited by 54
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Seo, M. H., Lee, J., Hong, S.-W., Rhee, E.-J., Park, S. E., Park, C. Y., Oh, K. W., Park, S. W., & Lee, W.-Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166913 · Cited by 37
Baik, M., Jeong, J. Y., Park, S. J., Yoo, S. P., Lee, J. O., Lee, J. S., Haque, M. N., & Lee, H.-J. (2020) · Genes & Nutrition · doi:10.1186/s12263-020-00673-1 · Cited by 24
Chen, K. L. A., Zhao, Y. C., Hieronymi, K., Smith, B. P., & Madak-Erdogan, Z. (2017) · PLOS ONE · doi:10.1371/journal.pone.0189911 · Cited by 19
Physiological and pathophysiological actions of insulin in the liver
Kubota, N., Kubota, T., & Kadowaki, T. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0192 · Cited by 19
The effect of early-life stress and chronic high-sucrose diet on metabolic outcomes in female rats
Maniam, J., Antoniadis, C. P., & Morris, M. J. (2015) · Stress · doi:10.3109/10253890.2015.1079617 · Cited by 13
Metadata
- Authors
- Inoue, M., Ohtake, T., Motomura, W., Takahashi, N., Hosoki, Y., Miyoshi, S., Suzuki, Y., Saito, H., Kohgo, Y., & Okumura, T.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 336
- Issue
- 1
- Pages
- 215-222
- ISSN
- 0006-291X
- Cited by
- 340
- References
- 2
- Language
- en
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
